Founded in 2022, Pythia Biotech is a Taiwan-based biotechnology innovator dedicated to transforming cancer research, drug discovery, and precision medicine. Born from cutting-edge research at National Tsing Hua University and Taipei Medical University, we bridge the gap between traditional preclinical models and clinical reality by engineering high-fidelity human-relevant tumor microenvironment platforms.
Our team integrates expertise in microphysiological systems (MPS), tumor biology, translational oncology, biomarker science, and multi-omics analytics. By combining these disciplines with AI-driven insights, we build next-generation platforms that mirror human disease biology, empowering researchers and pharmaceutical partners to accelerate therapeutic breakthroughs.
Pythia’s core technology is centered on its proprietary Tumor Microenvironment Chip (TME Chip) platform, which combines microfluidic engineering with biologically relevant tumor modeling. The platform is designed to reproduce key structural and functional features of the human tumor microenvironment in a controllable in vitro setting.
Core technologies
- Proprietary chip architecture for 3D tumor microenvironment modeling
The TME Chip features a central culture chamber suitable for 3D tumor spheroids or more complex multicellular tumor models, combined with adjacent perfusion channels that enable controlled fluid flow and introduction of immune cells or therapeutics. This architecture is intended to support tumor-stroma-ECM interaction and more physiologically relevant distribution behavior. - Microfluidic perfusion system
The platform incorporates dynamic flow conditions rather than static exposure. This improves modeling of nutrient/drug transport and supports studies of drug penetration, immune trafficking, and dynamic cellular response. - Oncology-oriented assay design
Unlike general-purpose organ-chip platforms, Pythia’s technology is built specifically for oncology applications. It is optimized around use cases such as efficacy testing, penetration analysis, immune-oncology assessment, and translational validation. - Modular platform development
Pythia is also developing a simplified pump/control system and supporting workflow to improve usability, reproducibility, and productization potential. This is important for future adoption by academic labs, biopharma companies, and translational research users. - Data generation capability linked to translational application
The platform is designed not only to culture cells, but to generate functional biological data that can guide research and preclinical decision-making. This supports the company’s long-term strategy of building product, service, and data value together.
Relevant patent applications
- TME Chip patents have been granted in both Taiwan and the United States.
- Patent strategy is currently focused on protecting the proprietary chip design, application workflow, and platform-related innovations. Relevant patent filing details can be disclosed upon request or after filing completion.
Tumor Microenvironment Chip (TME-Chip)
Pythia’s propriety TME-Chip combines 3D culture, dynamic perfusion, and compartmentalized tumor–stroma–immune interactions to recreate key features of the human tumor microenvironment. The platform supports drug penetration studies, immune migration analysis, real-time imaging, media sampling, and biomarker discovery to generate translationally relevant data for predictive oncology research.
Therapy Response Evaluation：Assess the anti-tumor activity of immunotherapies, targeted therapies, ADCs, chemotherapies, and combination treatments within a physiologically relevant tumor microenvironment. Our platform enables measurement of tumor growth inhibition, immune cell-mediated cytotoxicity, and treatment-induced changes that may influence therapeutic outcomes.
Drug Penetration & Delivery：Investigate the transport, distribution, and retention of therapeutic agents within complex tumor tissues. Our TME-Chip enables visualization of drug movement across stromal barriers and assessment of factors that may limit therapeutic exposure in solid tumors.
Tumor Microenvironment Biology：Recreate the cellular complexity of the tumor microenvironment to investigate interactions among tumor cells, fibroblasts, immune cells, and extracellular matrix components. Our platform supports mechanistic studies of cancer progression, immune suppression, and therapeutic resistance.
Patient-Derived Translational Testing：Integrate patient-derived samples into a controlled TME-Chip system to evaluate clinically relevant treatment responses, uncover patient heterogeneity, and support biomarker-driven precision oncology.
Multi-Omics and Biomarker Discovery：Integrate TME-Chip response data with multi-omics profiles to identify predictive biomarkers, uncover response mechanisms, and generate translational insights for drug development.
Explore how Pythia’s TME-Chip platform supports drug testing,immuno-oncology studies, therapeutic penetration analysis,biomarker discovery, and translational research in a dynamic 3D tumor microenvironment.